je.st
news
Tag: teva
Exclusive: Teva poised to raise its stake in Mylan - sources
2015-06-03 01:35:29| Biotech - Topix.net
The strategy is a sign of Teva's commitment to its $40 billion bid for Mylan, as the latter presses on with its own $34 billion hostile bid for over-the-counter drug company Perrigo Company Plc ( Teva last week disclosed a 1.8 percent stake in Mylan, which blasted the move as breaching U.S. antitrust laws because of the stake's size. U.S antitrust laws bar companies from acquiring stakes worth more than $76.3 million in rivals without first obtaining regulatory approval.
Tags: sources
exclusive
raise
stake
Teva Agrees to Pay $1.2 Billion in FTC's Pay-For-Delay Suit Against Cephalon
2015-06-01 22:33:23| Biotech - Topix.net
Recently, the FTC announced that it reached a settlement in its pay-for-delay lawsuit, FTC v. Cephalon Inc .
Teva pays $1.2 billion to settle pay-for-delay allegations
2015-05-28 19:32:28| Biotech - Topix.net
Federal regulators announced Thursday that Teva Pharmaceuticals Industries will pay $1.2 billion to settle charges that one of its subsidiaries illegally blocked the launch of low-cost generic versions of the blockbuster sleeping pill Provigil. The settlement is a major victory in the federal government's ongoing campaign against a common drug industry practice known as "pay-for-delay" deals.
Tags: pays
billion
settle
allegations
Mylan's Poison Pill May Fail to Deter Teva
2015-04-29 13:29:10| Biotech - Topix.net
An employee works with sterile products during the manufacture of pharmaceuticals inside Teva Pharmaceutical Industries Ltd.'s new factory in Godollo, Hungary. Photographer: Akos Stiller/Bloomberg Mylan NV's Dutch poison pill may give Teva Pharmaceutical Industries nothing more than a passing headache in its $40.1 billion attempt to buy the rival generic-drug maker.
Teva Announces FDA Approval Of ProAir RespiClick
2015-04-22 08:17:13| dairynetwork News Articles
Teva Pharmaceutical Industries Ltd., recently announced that the U.S. Food and Drug Administration (FDA) has approved ProAir RespiClick (albuterol sulfate) inhalation powder, a breath-actuated, multi-dose, dry-powder, short-acting beta-agonist (SABA) inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease; and for the prevention of exercise-induced bronchospasm (EIB) in patients 12 years of age and older
Tags: approval
announces
fda
teva
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] next »